

## InDex Pharmaceuticals updates shareholders list

**March 12, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that the list of shareholders on the homepage has been updated with information as of February 26, 2021.**

The 15 largest shareholders in InDex Pharmaceuticals Holding AB (publ) were as of February 26, 2021:

SHAREHOLDER	NUMBER OF SHARES	OWNERSHIP %	VOTES %
Linc AB	69 920 567	13.1%	13.1%
HBM Healthcare Investments	52 916 667	9.9%	9.9%
Fjärde AP-fonden	52 314 074	9.8%	9.8%
Försäkringsbolaget Avanza Pension	25 330 798	4.8%	4.8%
Handelsbanken Läkemedelsfond	25 000 000	4.7%	4.7%
SEB-Stiftelsen	19 047 617	3.6%	3.6%
SEB Life International	13 927 350	2.6%	2.6%
Nordnet Pensionsförsäkring AB	13 472 878	2.5%	2.5%
SEB Venture Capital	12 994 367	2.4%	2.4%
Stiftelsen Industrifonden	12 865 296	2.4%	2.4%
Bengt Thornberg	12 671 394	2.4%	2.4%
Staffan Rasjö	11 797 670	2.2%	2.2%
S-E-Bankens Utvecklingsstiftelse	10 000 000	1.9%	1.9%
Originat AB	7 000 000	1.3%	1.3%
Rune Pettersson, dödsbo	5 880 486	1.1%	1.1%

### For more information:

Peter Zerhouni, CEO

Phone: +46 8 122 038 50

E-mail: [peter.zerhouni@indexpharma.com](mailto:peter.zerhouni@indexpharma.com)

### Publication

The information was submitted for publication through the agency of the contact person set out above at 13:45 CET on March 12, 2021.

### InDex Pharmaceuticals in brief

InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The Company's lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis – a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.

InDex is based in Stockholm, Sweden. The Company's shares (ticker INDEX) are traded on Nasdaq First North Growth Market. Redeye AB with email address [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se) and phone number +46 8 121 576 90 is the Company's Certified Adviser. For more information, please visit [www.indexpharma.com](http://www.indexpharma.com).